ASCIA HAE Position Paper and Management Plan

The management of hereditary angioedema (HAE) is evolving, with more options for long-term prophylaxis that are now available. The ASCIA HAE position paper and management plan were updated in early 2020 to include these new treatments and to be consistent with international guidelines.  These changes are explained in an ASCIA Webinar about  HAE that was presented on 30 March 2020. An update to page 12 was made in July 2020, in response to the new product registration in New Zealand for prophylaxis of HAE attacks.
Updated ASCIA HAE Position Paper 2020

New ASCIA HAE Management Plan 2020 (with type in fields), which replaces the ASCIA HAE Action Plan.
pdfASCIA HAE Management Plan 2020129.80 KB

New ASCIA HAE Case Peer Review Form (with type in fields), which needs to be completed when requesting prophylaxis dose increases using a new treatment option - Berinert® SC.
pdfASCIA HAE Case Peer Review Form 202091.69 KB

ASCIA Hereditary Angioedema Position Paper 2020  ASCIA Management Plan HAE 2020  ASCIA HAE Case Peer Review Form 2020

Notice from Cipla regarding supply of icatibant

pdfCipla Icatibant Information109.55 KB

Notice from Takeda regarding delisting of Firazyr (icatibant) from PBS in Australia. 

pdfHCP_letter_Firazyr_PBS_Update_002726.08 KB

For information regarding supply of danazol in Australia please refer to  
ASCIA HAE Working Party members are listed at 

HAE Australasia is a support organisation for people with HAE and their carers in Australia and New Zealand.  For more information visit 

For information about how ASCIA information for health professionals is developed go to:

Content updated December 2020

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.